FibroGen plunges 43% after the company says there were errors in safety analyses data for its anemia drug candidate | Markets Insider

Generating your feed, please be patient ...

FibroGen plunges 43% after the company says there were errors in safety analyses data for its anemia drug candidate | Markets Insider | Zootzle